Laurent Nguyen
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Prediction of Monoclonal Antibodies Pharmacokinetics in Human: Identification of a Reference Neonatal Fc Receptor (FcRn) Binding Affinity Using Physiologically Based Pharmacokinetic (PBPK) Modeling.
Journal: ACS pharmacology & translational science
Published: October 09, 2025
Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.
Journal: Cancer chemotherapy and pharmacology
Published: July 06, 2025
Integrating Population Approaches With Physiologically Based Pharmacokinetic Models: A Novel Framework for Parameter Estimation.
Journal: CPT: pharmacometrics & systems pharmacology
Published: June 05, 2025
Cross-Species Extrapolation of Neonatal Fc Receptor (FcRn) Binding Affinity to Predict Monoclonal Antibody Pharmacokinetics in Humans Using Physiologically Based Pharmacokinetic Modeling (PBPK): Are We There Yet?
Journal: ACS pharmacology & translational science
Published: May 16, 2025
Prediction of CYP Down Regulation after Tusamitamab Ravtansine Administration (a DM4-Conjugate), Based on an In Vitro-In Vivo Extrapolation Approach.
Journal: Clinical pharmacology and therapeutics
Published: June 01, 2023
Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 24, 2021
Covariate analysis of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate, based on first-in-human study.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 09, 2021
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: September 01, 2021
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: February 12, 2021
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 27, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026